logo

Puma Biotechnology Inc. (PBYI)



Trade PBYI now with
  Date
  Headline
1/29/2021 8:02:49 AM Puma Biotechnology Presents Interim Results From Ongoing SUMMIT Trial Of Neratinib
1/15/2021 8:16:11 AM Puma Biotechnology Says Interim Results From Biliary Tract Cancers Cohort Of Phase 2 SUMMIT Basket Trial Of Neratinib
12/9/2020 7:54:11 PM Puma Biotechnology Presents Final Overall Survival Analysis From Phase III ExteNET Trial
7/16/2020 4:34:19 PM Puma Biotechnology: Licensing Partner STA Received Marketing Approval Of NERLYNX In Malaysia
2/26/2020 8:08:23 AM Puma Biotechnology Receives FDA Approval Of SNDA For Neratinib To Treat HER2-Positive Metastatic Breast Cancer
2/20/2020 5:25:07 PM Puma Biotechnology Reports Q4 Loss Per Share Of $0.29 Vs. $0.80 Last Year
12/2/2019 8:12:49 AM Puma Biotechnology, Pierre Fabre Agree To Extend Terms Of License Agreement
6/2/2019 9:19:51 AM Puma Biotechnology To Present Updated Interim Results From Phase II Clinical Trial Of Neratinib At ASCO Annual Meeting
4/1/2019 8:11:39 AM Puma Biotechnology And Pierre Fabre Enter Exclusive License Agreement
2/4/2019 9:57:02 PM Puma Biotechnology Announces Litigation Victory With Jury’s Decision
1/11/2019 8:10:39 AM Puma Biotechnology Enters Exclusive License Agreement With Knight Therapeutics
9/4/2018 8:16:33 AM EU Oks Puma NERLYNX For Extended Adjuvant Treatment Of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
6/29/2018 7:35:14 AM Puma Biotechnology Gets Positive CHMP Opinion Recommending Approval Of NERLYNX